Study of a new drug for advanced solid tumors with a specific genetic feature
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older (19 in South Korea).
- Your cancer is advanced (locally advanced or spread to other parts of the body) and standard treatments have not worked, or you can't tolerate them.
- Your tumor has a specific genetic change called MTAP deficiency, which your doctor can test for.
- You are in good general health, able to care for yourself and do light activities (ECOG score 0-1).
- You have adequate organ function and are willing to provide a tumor tissue sample before treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
This study tests a new drug, BMS-986504, to see how it is processed and removed from the body in people with certain advanced solid tumors. It is for patients whose cancer has a specific genetic change (MTAP deletion) and who have no other good treatment options.
This trial tests an experimental drug called BMS-986504, given alone or with other drugs, for people with advanced solid tumors that have a specific genetic change called a homozygous MTAP deletion. It may be an option if standard treatments are no longer working or aren't available.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.